With regard to biomarkers that may assist in the clinical assessment of muscle function alterations or disease progression in patients with ALS, albumin, CRP, haptoglobin, BuChE, and PON1 have all been linked to muscle activity or damage and are considered to play significant roles [27,30,68,69,70]. The gene discussed is PON1; the disease is amyotrophic lateral sclerosis.